<DOC>
	<DOCNO>NCT02476864</DOCNO>
	<brief_summary>A study conduct healthy adult investigate new macitentan tablet lead fate macitentan body ( time onset , time presence , amount blood ) market macitentan tablet .</brief_summary>
	<brief_title>Comparison Pharmacokinetic Properties Two Tablet Formulations Macitentan Healthy Adults</brief_title>
	<detailed_description>The purpose study establish biocomparison 2 type tablet contain macitentan : pediatric dispersible tablet adult film-coated tablet . A single oral dose tablet give healthy subject 2 different period separate washout phase 10 14 day . Biocomparison base comparison pharmacokinetic parameter macitentan two type tablet use specific statistical method . The pharmacokinetic parameter consider equivalent specific criterion define study protocol meet .</detailed_description>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Signed informed consent Healthy basis physical examination , vital sign ( systolic diastolic blood pressure , heart rate ) , 12lead ECG , laboratory test perform screen History clinical evidence disease and/or condition , might interfere absorption , distribution , metabolism excretion study drug Previous history fainting , collapse , syncope , orthostatic hypotension , vasovagal reaction History clinical evidence alcoholism drug abuse within 3 year period prior screen Excessive caffeine consumption Smoking within 3 month prior screen inability refrain smoke course study Previous treatment prescribe medication ( include vaccine ) overthe counter medication within 2 week prior first study drug administration Loss 250 mL blood within 3 month prior screen Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>macitentan</keyword>
	<keyword>biocomparison</keyword>
	<keyword>safety</keyword>
</DOC>